Pasar al contenido principal

IMPLICACION DE LA GLIA EN TAUPATIA: NUEVAS DIANAS TERAPEUTICAS

PID2021-125986OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

KEAP1-NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

  • Crisman, Enrique
  • Duarte, Pablo
  • Dauden, Esteban
  • Cuadrado, Antonio
  • Rodríguez-Franco, María Isabel
  • López, Manuela G.
  • León, Rafael
The transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is considered the master regulator of the phase II antioxidant response. It controls a plethora of cytoprotective genes related to oxidative stress, inflammation, and protein homeostasis, among other processes. Activation of these pathways has been described in numerous pathologies including cancer, cardiovascular, respiratory, renal, digestive, metabolic, autoimmune, and neurodegenerative diseases. Considering the increasing interest of discovering novel NRF2 activators due to its clinical application, initial efforts were devoted to the development of electrophilic drugs able to induce NRF2 nuclear accumulation by targeting its natural repressor protein Kelch-like ECH-associated protein 1 (KEAP1) through covalent modifications on cysteine residues. However, off-target effects of these drugs prompted the development of an innovative strategy, the search of KEAP1-NRF2 protein–protein interaction (PPI) inhibitors. These innovative activators are proposed to target NRF2 in a more selective way, leading to potentially improved drugs with the application for a variety of diseases that are currently under investigation. In this review, we summarize known KEAP1-NRF2 PPI inhibitors to date and the bases of their design highlighting the most important features of their respective interactions. We also discuss the preclinical pharmacological properties described for the most promising compounds., Enrique Crisman is the recipient of a PFIS fellowship of ISCIII. Pablo Duarte is the recipient of an FPU fellowship of the Spanish Ministry of education. Authors gratefully acknowledge funding from IS Carlos III, Comunidad de Madrid, and Spanish Research Agency. We thank Fundación Teófilo Hernando for its continued support. All schemes were created with Biorender.com. IS Carlos III cofinanced by the European Regional Development funds (FEDER) grant number PI17/01700. General Council for Research and Innovation of the Community of Madrid and European Structural Funds (grant B2017/BMD‐3827 NRF24ADCM. Spanish Ministry of Science, Innovation and Universities (grants PID2021‐123481OB‐I00, PID2021‐122650OB‐I00, PID2021‐125986OB‐I00, PDC2021‐121421‐I00, and PID2019‐110061RB‐I00). The authors have no financial support to disclose., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of a potent melatonin-based inhibitor of quinone reductase-2 with neuroprotective and neurogenic properties

  • Herrera-Arozamena, Clara
  • Estrada-Valencia, Martín
  • García-Díez, Guillermo
  • Pérez, Concepción
  • León, Rafael
  • Infantes, Lourdes
  • Morales-García, José A.
  • Pérez-Castillo, Ana
  • Sastre, Eric del
  • López, Manuela G.
  • Rodríguez-Franco, María Isabel
5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (3), whose structure was unambiguously elucidated by X-ray analysis, was identified as a multi-target compound with potential application in neurodegenerative diseases. It is a low nanomolar inhibitor of QR2 (IC50 = 7.7 nM), with greater potency than melatonin and comparable efficacy to the most potent QR2 inhibitors described to date. Molecular docking studies revealed the potential binding mode of 3 to QR2, which explains its superior potency compared to melatonin. Furthermore, compound 3 inhibits hMAO-A, hMAO-B and hLOX-5 in the low micromolar range and is an excellent ROS scavenger. In phenotypic assays, compound 3 showed neuroprotective activity in a cellular model of oxidative stress damage, it was non-toxic, and was able to activate neurogenesis from neural stem-cell niches of adult mice. These excellent biological properties, together with its both good in silico and in vitro drug-like profile, highlight compound 3 as a promising drug candidate for neurodegenerative diseases., Theauthors gratefully acknowledge the following financial supports: Spanish Ministry of Science, Innovation and Universities; Spanish Research Agency; and European Regional Development Funds (grants PID2021-122650OB-I00 to M.I.R.-F.; PDC2022-133809-I00 to M.G.L., R.L., and M.I.R.-F.; PID2021-123481OB-I00 to R.L.; PID2021125986OB-I00 to M.G.L.; PID2020-117400 GB-I00 to L.I.); General Council for Research and Innovation of the Community of Madrid (grant P2022/BMD-7230 to M.G.L., R.L., and M.I.R.-F.); Spanish National Research Council (CSIC, grant PIE-202480E175 to M.I.R.-F.) Compound 3 X-ray experiments were performed at BL13-XALOC beamline at ALBA Synchrotron with the collaboration of ALBA staff. We thank the Spanish Ministry of Science, Innovation and Universities for the fellowships FPU22/03672 to G.G.-D. and FPU18/00630 to E.dS. The authors acknowledge the support of the European COST Action CA20121 (BenBedPhar) and the Fundación Teófilo Hernando, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The mitochondrial Na+/Ca2+ exchanger NCLX is implied in the activation of hypoxia-inducible factors

  • Choya-Foces, C.
  • Navarro, Elisa
  • Rios, C. de los
  • López, M.G.
  • Egea, J.
  • Hernansanz-Agustín, Pablo
  • Martínez-Ruiz, A.
Eukaryotic cells and organisms depend on oxygen for basic living functions, and they display a panoply of adaptations to situations in which oxygen availability is diminished (hypoxia). A number of these responses in animals are mediated by changes in gene expression programs directed by hypoxia-inducible factors (HIFs), whose main mechanism of stabilization and functional activation in response to decreased cytosolic oxygen concentration was elucidated two decades ago. Human acute responses to hypoxia have been known for decades, although their precise molecular mechanism for oxygen sensing is not fully understood. It is already known that a redox component, linked with reactive oxygen species (ROS) production of mitochondrial origin, is implied in these responses. We have recently described a mechanism by which the mitochondrial sodium/calcium exchanger, NCLX, participates in mitochondrial electron transport chain regulation and ROS production in response to acute hypoxia. Here we show that NCLX is also implied in the response to hypoxia mediated by the HIFs. By using a NCLX inhibitor and interference RNA we show that NCLX activity is necessary for HIF-α subunits stabilization in hypoxia and for HIF-1-dependent transcriptional activity. We also show that hypoxic mitochondrial ROS production is not required for HIF-1α stabilization under all circumstances, suggesting that the basal cytosolic redox state or other mechanism(s) could be operating in the NCLX-mediated response to hypoxia that operates through HIF-α stabilization. This finding provides a link between acute and medium-term responses to hypoxia, reinforcing a central role of mitochondrial cell signalling in the response to hypoxia., We thank Tamara Villa-Piña, Elena Ramos, Tamara Oliva and Esther Fuertes-Yebra for technical assistance. We also thank Dr. John Elrod (Temple University, USA), Dr. José Antonio Enríquez (CNIC, Spain) and Dr. Israel Sekler (Ben Gurion University of the Negev, Israel) for providing us materials needed to complete the study. This research has been financed by grants from the Spanish Government (partially funded by the European Union ERDF “A way of making Europe” and NextGenerationEU): RedoxStroke (RTI2018- 094203-B-I00), excellence network RED2018-102576-T, NCLRedoX (PID2021-124688OB-I00), NCLXtroke (PDC2022-133246-I00), PID2021-125986OB-I00 and PID2022-139936OA-I00 from AEI (MICIU/ AEI/10.13039/501100011033); PI15/00107, PI22/00362 and RICORS- ICTUS (RD21/0006/0009) from Instituto de Salud Carlos III (ISCIII) and fellowships IJC2020-042679-I (MICIU) and RYC2022-036516-I (MICIU) to P.H.-A. from AEI and FPU18/03475 to C.C.-F. from MICIU, and by a grant from the Fundación Domingo Martínez.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

  • Cuadrado, Antonio
  • Cazalla, Eduardo
  • Bach, A.
  • Bathish, B.
  • Naidu, S. D.
  • DeNicola, G. M.
  • Dinkova-Kostova, A. T.
  • Fernández-Ginés, Raquel
  • Grochot-Przeczek, A.
  • Hayes, J. D.
  • Kensler, T. W.
  • León, Rafael
  • Liby, K. T.
  • López, M. G.
  • Manda, Gina
  • Shivakumar, A. K.
  • Hakomäki, H.
  • Moerland, J. A.
  • Rojo, Ana I.
  • Sykiotis, G. P.
  • Taguchi, K.
  • Valverde, Ángela M.
  • Yamamoto, M.
  • Levonen, A. L.
This review is dedicated to the memory of Dr. Karen T. Liby, who passed away during the final editing of the manuscript. During her academic career, Karen made numerous extensive contributions to the pharmacology of Nrf2 activators, particularly to the preclinical development of the cyanoenone triterpenoids as multifunctional agents for prevention and treatment of chronic disease. Karen’s untimely passing is a huge loss for the Nrf2 community worldwide. Her kind personality and scientific rigour will be greatly missed., Nuclear factor erythroid 2-related factor 2 (NRF2) is a redox-activated transcription factor regulating cellular defense against oxidative stress, thereby playing a pivotal role in maintaining cellular homeostasis. Its dysregulation is implicated in the progression of a wide array of human diseases, making NRF2 a compelling target for therapeutic interventions. However, challenges persist in drug discovery and safe targeting of NRF2, as unresolved questions remain especially regarding its context-specific role in diseases and off-target effects. This comprehensive review discusses the dualistic role of NRF2 in disease pathophysiology, covering its protective and/or destructive roles in autoimmune, respiratory, cardiovascular, and metabolic diseases, as well as diseases of the digestive system and cancer. Additionally, we also review the development of drugs that either activate or inhibit NRF2, discuss main barriers in translating NRF2-based therapies from bench to bedside, and consider the ways to monitor NRF2 activation in vivo., U.S. National Institutes of Health, R35 CA197222 (T.W.K.). PID- 2021-122766OB-1363 100 funded by MICIU/AEI/10.13039/ 501100011033 and by ERDF/EU (A.M.V.). National Science Centre grant OPUS (2021/43/B/NZ4/02130) (A.G-P). Swiss National Science Foundation grants 310 030_212 558 and IZCOZ0_205 415 (G.P.S.). Lundbeck Foundation (grant R366-2021-270 (A.B.). Medical Research Council UK [MR/T014644/1 (J.D.H., B.B., A.T.D-K) and MR/ W023806/1 (A T.D-K)], Biotechnology and Biological Sciences Research Council UK (BB/T508111/1 and BB/X00029X/1) (A.T.D-K), Tenovus Scotland (T22-08) (S.DN, A.T.D-K), and Reata Pharmaceuticals/Biogen (S.DN, A.T.D-K). Spanish Ministry of Science, Innovation and Universities (PID-2021-122766OB-100, PDC2021-121 421-I00, PDC2022-133 765-I00), CIBERNED/ISCIII (CB06/05/0010), and The Autonomous Community of Madrid (P2022/BMD-7230) (A.C., A.I.R.). FPU contract of MIU (Ministry of Universities FPU2021, FPU21/02505) (E.C.). Spanish Ministry of Science (grant PID2021-123481OB-I00), Comunidad de Madrid (grant P2022/BMD-7230-CAM-22), and Fundación Teófilo Hernando” (R.L.). Romania Ministry of Research, Innovation and Digitization through the Nucleu grant PN23.16.02.01 (G.M.). Spanish Ministry of science innovation and universities Refs PDC2022-133 809-I00 and PID2021-125986OB-I00 and General Council for Research and Innovation of the Community of Madrid Ref. P2022/BMD-7230 to (M.G.L.). NIH National Cancer Institute: NIH F31 CA275239 (J.A.M). Cancer Foundation Finland, Sigrid Juselius Foundation (A.L.L.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Long-term NRF2-driven microglial repopulation mitigates microgliosis, neuronal loss and cognitive deficits in tauopathy

  • Viqueira, Lucía
  • Navarro, Elisa
  • Negredo, Pilar
  • Bernal, Juan Antonio
  • Rodríguez-Franco, María Isabel
  • Tortosa, Elena
  • López, Manuela G
Tauopathies, including Alzheimer's disease, feature chronic microglial reactivity that drives neuroinflammation and disease progression. Pharmacological microglial depletion and subsequent repopulation using colony-stimulating factor 1 receptor inhibitors have emerged as a potential therapeutic strategy to reprogram dysfunctional microglia. Despite promising short-term results, the long-term efficacy and pharmacological modulation of repopulated microglia remain poorly understood. Here, we investigated the long-term effects of microglial repopulation alone and in combination with the activation of the cytoprotective nuclear factor erythroid 2 p45-related factor 2 (NRF2) in an in vivo AAV-hTauP301L induced model. Integrating different behavioural, immunohistological and transcriptomic analysis, we evaluated cognitive function, tau pathology, neuronal survival and glial reactivity. We found that, whereas microglial repopulation alone did not significantly affect disease progression, NRF2-driven microglial replenishment sustained cognitive function, prevented hippocampal neuronal loss and restored microglial phenotype. Transcriptomic analyses further revealed that the combined treatment modulated tau- associated mitochondrial gene expression changes. These results highlight the importance of shaping the fate of self-renewed microglia and propose NRF2-mediated microglial repopulation as a potential pharmacological strategy for the treatment of tauopathies., This work was supported by the Spanish Ministry of Science, Innovation and Universities (PDC2022-133809-I00 and PID2021- 125986OB-I00 to MGL; PID2021-122650OB-I00 to MIRF; PID2022- 139936OA-I00 to EN and FPU20/03747 fellowship to LV); and the General Council for Research and Innovation of the Community of Madrid (P2022/BMD-7230 to MGL and 2020-T1/BMD-19886 to ET)., Peer reviewed